Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This real-world analysis evaluated docetaxel plus nintedanib in patients with advanced pulmonary adenocarcinoma after chemotherapy and immune checkpoint inhibitor failure, for whom treatment options are limited. Data were sourced retrospectively from seven German centers. Of 93 patients, overall response rate was 41.4% (disease control rate: 75.9%). Of 57 patients given third-line docetaxel plus nintedanib, overall response rate was 50.0% (disease control rate: 82.7%). Median overall survival following third-line docetaxel plus nintedanib was 8.4 months. Adverse events were consistent with the known safety profile of docetaxel plus nintedanib. To date, this was the largest retrospective, real-world analysis of docetaxel plus nintedanib after chemotherapy-immunotherapy failure, indicating that docetaxel plus nintedanib offers meaningful clinical benefits in this setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2021-0424 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Patients with advanced non-small cell lung cancer (NSCLC) who progress after chemotherapy and immune checkpoint inhibitors (ICIs) need effective second-line treatments. The combination of nintedanib and docetaxel has shown promise, particularly post-ICI progression. This study evaluates the efficacy, safety, and prognostic factors of this regimen in a cohort from the Galician Lung Cancer Group.
View Article and Find Full Text PDFToxicity Profile and Efficacy of Docetaxel Following Paclitaxel- or Pemetrexed-Platinum Chemotherapy Alone or in Combination With Immune Checkpoint Inhibitors in NSCLC Patients: A Single Institution Retrospective Analysis.
Cancer Control
April 2025
Department of Medicine V, University Hospital, LMU Munich, München, Germany.
BackgroundDocetaxel alone or in combination with ramucirumab or nintedanib is recommended as second-line treatment in metastatic non-small cell lung cancer (NSCLC) patients after progression on first-line platinum-base chemotherapy in combination with immune-checkpoint inhibitors (ICI). The purpose of our study was to compare the toxicity profile and efficacy of docetaxel after paclitaxel- or pemetrexed-platinum chemotherapy alone or in combination with ICI.Patients und MethodsMetastatic NSCLC patients treated with docetaxel after pemetrexed or paclitaxel-platinum with chemotherapy with or without ICI were included in our retrospective analysis.
View Article and Find Full Text PDFCancer Therapy-Induced Cardiotoxicity: Results of the Analysis of the UK DEFINE Database.
Cancers (Basel)
January 2025
School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK.
Background: The accelerated development of novel cancer therapies necessitates a thorough understanding of the associated cardiotoxicity profiles, due to their significant implications for the long-term health and quality of life of cancer survivors.
Objectives: The aim of this study was to determine the association between cardiotoxicity and non-small cell lung cancer (NSCLC) treatments using a hospital medicines usage database in England.
Methods: An observational study based on a retrospective design using real-world data from the UK DEFINE database was performed.
A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNIS.
Transl Lung Cancer Res
December 2024
Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, UK.
Background: Anti-angiogenic agents, such as nintedanib and ramucirumab, when combined with docetaxel, are subsequent treatment options in patients with non-small cell lung cancer (NSCLC) who have failed on first-line chemotherapy or immunochemotherapy. However, to date, there are no validated predictive biomarkers for efficacy of anti-angiogenic therapies in this setting. The aim of this study was to explore whether genetic or genomic markers, alone or combined with clinical covariates, could be used to predict overall survival (OS) in patients with NSCLC who are eligible for treatment with nintedanib plus docetaxel.
View Article and Find Full Text PDFClinical advances and challenges in targeting FGF/FGFR signaling in lung cancer.
Mol Cancer
November 2024
Department of Pharmacy, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, P. R. China.
Fibroblast growth factors (FGFs) and their receptors regulate numerous cellular processes, such as metabolism and signal transduction, but can also drive tumorigenesis. Specifically, in lung cancer, the overexpression of FGFs, as well as the amplification, mutation and fusion of FGFR genes, are closely linked to the initiation, progression and resistance of the disease, suggesting that targeting FGF/FGFR is an attractive therapeutic strategy for lung cancer treatment. Nintedanib, a multitarget tyrosine kinase inhibitor (TKI) used in combination with docetaxel, has shown some success as a second-line therapy for lung cancer.
View Article and Find Full Text PDF